8-K: Precision BioSciences' Hepatitis B Trial Shows Early Promise

Precision BioSciences announced positive Phase 1 safety and efficacy data for its PBGENE-HBV gene editing therapy for chronic hepatitis B, extending its cash runway to mid-2027.

Summary

• Precision BioSciences reported positive Phase 1 safety and efficacy data for PBGENE-HBV, its gene editing therapy for chronic hepatitis B, from the ELIMINATE-B clinical trial.
• Cohort 1 (0.2 mg/kg dose) showed PBGENE-HBV was well-tolerated in all three patients, with no adverse events above Grade 2, serious adverse events, or dose-limiting toxicities.
• All three patients in Cohort 1 demonstrated substantial Hepatitis B surface antigen (HBsAg) reduction, with best responses of 56%, 69%, and 47% compared to baseline levels.
• One patient (33% of Cohort 1) achieved a durable HBsAg reduction of approximately 50% from baseline, maintained for seven months after the initial dose, providing evidence of a durable antiviral response by editing viral DNA.
• Initial safety data from Cohort 2 (0.4 mg/kg dose) also showed no adverse events above Grade 2, no serious adverse events, nor dose-limiting toxicities in patients dosed so far.
• The company extended its expected cash runway to the second half of 2027, providing over two years of operating cash, enabling potential Phase 2 for PBGENE-HBV and a pivotal study for PBGENE-DMD.
• An operating efficiency program initiated in July 2025 is expected to reduce annual operating expenses in 2026 and 2027 by approximately $25 million compared to 2025 levels.

Sentiment

Score: 8

Explanation: The filing presents strong positive early clinical data for a novel gene editing therapy in a high unmet need area, coupled with a significant extension of cash runway, indicating good progress and financial stability. While early-stage, the results are promising and the strategic financial moves are favorable.

Positives

• PBGENE-HBV was well-tolerated in Cohort 1 (0.2 mg/kg) and initial Cohort 2 (0.4 mg/kg), with no serious adverse events or dose-limiting toxicities observed.
• All three patients in Cohort 1 showed substantial HBsAg reduction, with best responses ranging from 47% to 69%.
• One patient in Cohort 1 achieved a durable HBsAg reduction of approximately 50% for seven months, demonstrating the therapy's ability to drive a durable antiviral response by editing viral DNA.
• The Data Monitoring Committee (DMC) recommended initiating Cohort 3 due to the favorable safety profile of Cohorts 1 and 2.
• Cash runway extended to the second half of 2027, providing more than two years of operating cash and enabling progression to later-stage trials (Phase 2 for PBGENE-HBV, pivotal study for PBGENE-DMD).
• Dr. Mark Sulkowski, a renowned expert in hepatitis B, expanded his role to Head Clinical Development Advisor, strengthening the clinical development team.
• The company initiated an operating efficiency program to reduce annual operating expenses by approximately $25 million in 2026 and 2027.

Negatives

• Two of three patients in Cohort 1 eventually returned to baseline HBsAg levels, suggesting the lowest dose may not be sufficient for sustained response in all patients.
• One patient in Cohort 2 experienced a transient infusion-related serious adverse event that led to dose interruption, though it quickly resolved and was deemed not dose-related or dose-limiting by the DMC.

Risks

• Ability to become profitable.
• Ability to procure sufficient funding to advance programs.
• Risks associated with capital requirements, anticipated cash runway, and ability to raise additional capital.
• Predictability of operating expenses.
• Limited operating history.
• Progression and success of programs and product candidates.
• Limited ability or inability to assess the safety and efficacy of product candidates.
• Risk that other genome-editing technologies may provide significant advantages over ARCUS technology.
• Dependence on ARCUS technology.
• Initiation, cost, timing, progress, achievement of milestones, and results of research and development activities and preclinical and clinical studies.
• Public perception about genome editing technology and its applications.
• Competition in the genome editing, biopharmaceutical, and biotechnology fields.
• Ability to identify, develop, and commercialize product candidates.
• Pending and potential product liability lawsuits and penalties.
• U.S. and foreign regulatory landscape applicable to product candidates.
• Ability to advance product candidates into, and successfully design, implement, and complete, clinical trials.
• Potential manufacturing problems.
• Delays or difficulties in patient enrollment.
• Changes in interim top-line and initial data.
• Product candidates not working as intended or causing undesirable side effects.
• Risks associated with applicable healthcare, data protection, privacy, and security regulations.
• Ability to obtain orphan drug designation or fast track designation.
• Ability to obtain and maintain regulatory approval.
• Rate and degree of market acceptance.
• Ability to effectively manage growth.
• Ability to attract, retain, and motivate executives and personnel.
• Effects of system failures and security breaches.
• Insurance expenses and exposure to uninsured liabilities.
• Effects of tax rules.
• Effects of any pandemic, epidemic, or outbreak of an infectious disease.
• Success of existing collaboration and other license agreements, and ability to enter new arrangements.
• Current and future relationships with and reliance on third parties including suppliers and manufacturers.
• Ability to obtain and maintain intellectual property protection.
• Potential litigation relating to infringement or misappropriation of intellectual property rights.
• Effects of natural and manmade disasters, public health emergencies, and other natural catastrophic events.
• Effects of sustained inflation, supply chain disruptions, and major central bank policy actions.
• Market and economic conditions.
• Risks related to ownership of common stock, including fluctuations in stock price.
• Ability to meet Nasdaq listing requirements.

Future Outlook

Precision BioSciences plans to complete dosing of Cohort 2 and commence dosing Cohort 3 in the ELIMINATE-B study, with a data update expected later in 2025. The company intends to evaluate increasing and more frequent doses of PBGENE-HBV to establish an optimal dose and schedule for a complete cure. The extended cash runway to mid-2027 is expected to enable the commencement of a Phase 2 study for PBGENE-HBV and a pivotal study for the PBGENE-DMD program.

Management Comments

• "This exciting dataset provides the first clinical evidence of substantial HBsAg reductions as a result of direct cccDNA elimination and/or inactivation of integrated HBV DNA in all patients, even at this lowest dose level. PBGENE-HBV was both well-tolerated and highly active in all chronic hepatitis B patients after three dose administrations. The data from the first cohort supports the tolerability of multiple administrations of PBGENE-HBV and gives me reason to believe that we can safely escalate the dose and increase drug exposure of this novel technology to potentially drive a complete cure by not leaving any viral DNA behind." Man-Fung Yuen, MBBS, M.D., PhD, DSc ELIMINATE-B Investigator.
• "We are pleased to continue to observe an impressive clinical safety profile, with transient changes in liver transaminases remaining less than three times the upper limit of normal with no clinical symptoms for both dose levels. Given the low starting dose of 0.2 mg/kg and dosing every eight weeks, we did not expect to eliminate 100% of the virus in Cohort 1 and based on dose-dependency observed in nonclinical models we anticipate deeper and more durable responses as we progress in the study. Given our mechanism, proof of sustained viral marker reduction as a result of viral editing in one patient was critical to reinforce the thesis behind PBGENE-HBV." Cassie Gorsuch, PhD, Chief Scientific Officer.
• "We have made significant progress advancing our lead asset PBGENE-HBV, and we believe the early Phase 1 data supports first signs of viral elimination of chronic hepatitis B. Our early data shows that we have a novel, safe and active drug in all patients treated, with a durable effect in one-third of patients, even at the lowest dose level. To deliver a complete cure and reduce long term liver disease and cancer risk, we must ensure we are eliminating the root cause of disease replication the cccDNA. We are generating molecular data using liver biopsies to demonstrate PBGENE-HBVs mechanism of action to eliminate cccDNA and inactivate integrated HBV DNA." Michael Amoroso, President and Chief Executive Officer.
• "As we advance the clinical evaluation of PBGENE-HBV, his wealth of experience will be a critical resource to help guide our medical and clinical development organization. We are thrilled to expand his involvement at such an important time for the Company and look forward to benefitting from his hands-on strategic expertise to help us drive ELIMINATE-B towards later phase studies." Michael Amoroso, President and Chief Executive Officer, on Dr. Mark Sulkowski's expanded role.

Industry Context

Chronic hepatitis B affects an estimated 300 million people globally, with 15-40% developing complications like cirrhosis, liver failure, or liver cancer, accounting for most HBV-related deaths. Current treatments primarily suppress the virus but rarely achieve a functional cure (estimated 1-3% success rate) because they do not eradicate HBV cccDNA, requiring lifelong administration. PBGENE-HBV is positioned as the first and only clinical gene editing modality specifically designed to eliminate cccDNA and inactivate integrated HBV DNA, aiming for a complete cure and potentially raising the functional cure rate towards the global goal of 30%.

Comparison to Industry Standards

• Current treatments for chronic hepatitis B rarely lead to a functional cure, with an estimated success rate of only 1-3%.
• The global goal for a functional cure rate for hepatitis B is 30%.
• PBGENE-HBV is presented as the "first and only clinical modality designed to eliminate covalently closed circular DNA (cccDNA) and inactivate integrated DNA, with the goal of complete cure," differentiating it from existing therapies that cannot alter cccDNA.
• The company aims to raise the achievable functional cure rate from the current 1-3% to the global goal of 30% with PBGENE-HBV.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to promising early clinical data, extended cash runway, and strategic cost reductions, potentially increasing company value and reducing near-term dilution risk.
• Patients (Chronic Hepatitis B): Potential for a novel, curative treatment option where current therapies are limited, offering hope for a complete cure and reduced risk of liver disease/cancer.
• Employees: Impacted by operating efficiency program, including employment-related reductions in early research, but overall stability enhanced by extended cash runway and focus on clinical programs.
• Investment Professionals/Analysts: Provides new data points for valuation and risk assessment, supporting further analysis of the company's pipeline and financial health.

Next Steps

• Complete dosing of all three patients with three planned dose administrations in Cohort 2 of the ELIMINATE-B study.
• Commence dosing Cohort 3 in the ELIMINATE-B study.
• Provide a data update for the ELIMINATE-B study later in 2025.
• Evaluate PBGENE-HBV at increasing and more frequent doses until a maximum tolerated dose is reached.
• Establish the right dose and administration schedule for PBGENE-HBV leading to a complete cure and optimal therapeutic index.
• Generate molecular data using liver biopsies to demonstrate PBGENE-HBV's mechanism of action (cccDNA elimination and integrated HBV DNA inactivation).
• File an IND and/or CTA for the PBGENE-DMD program.
• Commence a Phase 2 study for PBGENE-HBV.
• Commence a pivotal study for PBGENE-DMD.
• Expand the ELIMINATE-B study to clinical trial sites in the U.S. and U.K.

Key Dates

Recommendation

While the early Phase 1 data for PBGENE-HBV is promising, showing good safety and initial signs of efficacy, it is still very early stage clinical development. The durable response was observed in only one-third of patients in the lowest dose cohort, and further dose escalation and optimization are needed. The extended cash runway is a significant positive, providing financial stability. However, the inherent risks of clinical trials, particularly in gene editing, remain high. A "hold" recommendation acknowledges the positive developments and long-term potential while advising caution given the early stage and remaining uncertainties. Investors should monitor future data updates and dose escalation results closely.

Keywords

Gene editing, Hepatitis B, PBGENE-HBV, ELIMINATE-B, ARCUS platform, Clinical trial, Phase 1, cccDNA, HBsAg, Chronic hepatitis B, Biotechnology, Gene therapy, Clinical stage, Duchenne muscular dystrophy, PBGENE-DMD